ANNX
NASDAQ · Biotechnology
Annexon Inc
$5.69
+0.17 (+3.08%)
Open$5.62
Previous Close$5.52
Day High$6.03
Day Low$5.56
52W High$7.18
52W Low$1.60
Volume—
Avg Volume2.06M
Market Cap897.04M
P/E Ratio—
EPS$-1.34
SectorBiotechnology
Analyst Ratings
Strong Buy
16 analysts
Price Target
+617.2% upside
Current
$5.69
$5.69
Target
$40.81
$40.81
$23.52
$40.81 avg
$51.70
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 226.99M | 205.43M | 221.74M |
| Net Income | -28,556,645 | -21,219,491 | -26,718,856 |
| Profit Margin | -12.6% | -10.3% | -12.1% |
| EBITDA | -33,644,452 | -28,464,345 | -32,841,743 |
| Free Cash Flow | -13,512,889 | -15,079,405 | -14,899,369 |
| Rev Growth | +7.5% | +20.0% | +0.3% |
| Debt/Equity | 0.32 | 0.38 | 0.38 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $201.55 | -0.57% | 88.1 | 372.29B |
| AMGN | Amgen Inc | $331.70 | +0.79% | 22.7 | 176.88B |
| GILD | Gilead Sciences Inc | $131.33 | -2.04% | 19.3 | 163.92B |
| VRTX | Vertex Pharmaceuticals Inc | $429.82 | +1.13% | 27.7 | 109.50B |
| REGN | Regeneron Pharmaceuticals | $714.89 | +0.82% | 16.5 | 74.30B |
| ALNY | Alnylam Pharmaceuticals Inc | $295.05 | -0.29% | 130.4 | 40.90B |